Drug Trial Radar · NCT07226856
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
43
Planned (sponsor's estimate)
Start
Dec 12, 2025
Primary completion
Feb 28, 2027
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests the safety, side effects and best dose of BMS-986340 in combination with nivolumab, gemcitabine, and nab-paclitaxel and how well it works in treating patients with pancreatic adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that has come back after a period of improvement (recurrent). BMS-986340 is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving BMS-986340 in combination with nivolumab, gemcitabine, and nab-paclitaxel may be safe, tolerable, and/or effective in treating patients with metastatic or recurrent pancreatic adenocarcinoma.
Conditions
- Metastatic Pancreatic Adenocarcinoma
- Recurrent Pancreatic Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy ProcedureProcedure
Undergo tissue biopsy
Biospecimen CollectionProcedure
Undergo urine and blood sample collection
Computed TomographyProcedure
Undergo CT
GemcitabineDrug
Given IV
ImzokitugBiological
Given IV
Magnetic Resonance ImagingProcedure
Undergo brain MRI
Nab-paclitaxelDrug
Given IV
NivolumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of significant adverse events (AEs) (Safety Run-in)Time frame: During cycle 1 (cycle length = 28 days)
- Objective response rate (Phase II)Time frame: Up to 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.